Background: The kinesin , a mitosis-associated protein, is overexpressed in many cancers. Here we explored the clinical significance of in hepatocellular carcinoma (HCC).

Methods: HCC tissues from surgical resection were collected. Total RNA was prepared from tumorous and nontumorous parts. expression levels were correlated with overall survival (OS) and disease-free survival (DFS). In vitro efficacy of LGI-147, a specific inhibitor, was tested in HCC cell lines. In vivo efficacy of inhibition was investigated in a xenograft model.

Results: A total of 108 HCC samples were included. The patients were divided into three tertile groups with high, medium, and low expression levels. OS of patients with low expression was better than that of patients with medium and high expression (median, 155.6 vs. 75.3 vs. 57.7 months, = 0.002). DFS of patients with low expression was also better than that of patients with medium and high expression (median, 126.3 vs. 46.2 vs. 39.4 months, = 0.001). In multivariate analyses, the associations between expression and OS ( < 0.001) or DFS remained ( < 0.001). LGI-147 reduced cell growth via cell cycle arrest and apoptosis and induced accumulation of abnormal mitotic cells. In the xenograft model, the tumor growth rate under LGI-147 treatment was significantly slower than under the control.

Conclusion: High expression was associated with poor HCC prognosis. In vitro and in vivo evidence suggests that may be a reasonable therapeutic target for HCC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303881PMC
http://dx.doi.org/10.3390/cells10071698DOI Listing

Publication Analysis

Top Keywords

low expression
12
high expression
12
therapeutic target
8
hepatocellular carcinoma
8
expression
8
expression levels
8
patients low
8
expression better
8
better patients
8
patients medium
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!